Fortaz Articles
AstraZeneca and Forest initiate Ph III trials of CAZ-AVI
18 October 2011
NXL104/ceftazidime enters Ph II cUTI trial
17 November 2008
Novexel and Forest sign NXL104 deal
28 January 2008
Strong Ph III data for J&J/Basilea's ceftobiprole
15 October 2007
Opposite ratings for Swiss bio firms Arpida and Basilea
8 October 2007
90% cure rate for MRSA cSSSI with J&J's ceftobiprole
1 October 2007
Basilea's ceftobiprole meets Ph II endpoint
22 January 2007
Basilea's ceftobiprole meets Ph II endpoint
22 January 2007
Novexel's NXL104 enters Ph I testing
22 December 2006
Tanabe's turnover up 1.3% by 3rd-qtr 2005
20 February 2006
GW withdraws Raxar on safety concerns
28 October 1999
Will New Wave Of Antibiotics Fight Resistance?
23 October 1997
Antibiotic Effects Differ In Sepsis
23 September 1996
Glaxo Wellcome Licences Otsuka's Grepafloeacin
10 June 1996
China's Antibiotic Market Valued At $109 Million Plus
21 August 1995
Glaxo Interim Profits Up 10% On 2% Sales Rise
13 February 1995
AHP Bid For Cyanamid Will Broaden Product Range
15 August 1994
TAZOCIN EFFECTIVE IN SEVERE INFECTION
16 May 1994
LIKELY IMPACT ON DRUG FIRMS OF ITALIAN REFORMS
17 January 1994
VARIABLE RESISTANCE WITH CEPHALOSPORINS
8 November 1993
ENCOURAGING RESULTS FOR ZENECA'S MERREM
5 July 1993
IMMUNOSTIMULANT ACTION FOR CEFTAZIDIME?
20 April 1992
Showing 1-25 of 25 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
